493 results on '"Maurer, Mathew S"'
Search Results
2. Treatment of ATTR Amyloidosis: From Stabilizers to Gene Editing
3. High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy
4. Unlocking Diversity in Cardiovascular Clinical Research: Lessons from the SCAN-MP (Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations) Study
5. Treatment of transthyretin cardiac amyloidosis
6. The Association between Pre-operative Pectoralis Muscle Quantity and Outcomes after Cardiac Transplantation
7. Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety
8. Mortality After Alcohol Septal Ablation vs. Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy
9. Cardiac Amyloidosis Due to Transthyretin Protein
10. Gait abnormalities in older adults with transthyretin cardiac amyloidosis
11. Comprehensive RV Hemodynamic Assessment With Pressure-Volume Analysis During Impella Support
12. Temporal Outcomes of Patients Diagnosed With Transthyretin Cardiac Amyloidosis
13. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin‐mediated amyloidosis with polyneuropathy
14. Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement
15. Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic study
16. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
17. Prediction of cardiac death in patients with hypertrophic cardiomyopathy using plasma adipokine levels
18. Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study
19. Primary Results From APOLLO-B Open-label Extension Study Of Patisiran In Patients With Transthyretin Cardiac Amyloidosis
20. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy
21. Impact of Interventricular Interaction on Ventricular Function
22. Assessing and managing frailty in advanced heart failure: An International Society for Heart and Lung Transplantation consensus statement
23. Reduced early mortality with Daratumumab‐based frontline therapy in AL amyloidosis: A retrospective cohort study
24. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis
25. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
26. Abstract 12080: Comprehensive Proteomics Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Severe Forms of Hypertrophic Cardiomyopathy
27. Abstract 13090: Clinical Burden of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the USA From 2004 to 2022
28. Abstract 14418: Prevalence, Characteristics, and Factors Associated With Atrial Fibrillation and Flutter in Patients With Transthyretin Cardiac Amyloidosis
29. Abstract 14362: The Columbia Score Predicts Incident Atrial Fibrillation and Flutter in Patients With Transthyretin Cardiac Amyloidosis
30. Abstract 11317: Comprehensive Plasma Proteomics Profiling Identifies Signaling Pathways Dysregulated in Genotype-Positive versus Genotype-Negative Patients With Hypertrophic Cardiomyopathy
31. Abstract 13273: APOLLO-B, a Study of Patisiran in Patients With Transthyretin Cardiac Amyloidosis: Primary Long-Term Results From the Open-Label Extension Period
32. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
33. The way to a man’s heart: prostate samples for the early detection of transthyretin cardiomyopathy
34. Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction
35. Heterogeneous worldwide access and pricing of Tafamidis
36. The Emerging Significance of Amyloid Deposits in the Ligamentum Flavum of Spinal Stenosis Patients: A Review
37. Cardiac Amyloidosis
38. Contributors
39. Advanced Heart Failure Therapies for Hypertrophic Cardiomyopathy
40. Signaling Pathways Associated with Prior Cardiovascular Events in Hypertrophic Cardiomyopathy
41. Difficult Diagnoses Are Often Undertreated
42. Gene Silencing Therapy in Hereditary (Variant) Transthyretin Cardiac Amyloidosis: A Puzzling Case of Decreasing Pyrophosphate Uptake on Scintigraphy
43. Prediction of worsening heart failure in hypertrophic cardiomyopathy using plasma proteomics
44. Reply to the letter: In the thick of it: highlighting the importance of SPECT imaging
45. Discriminative Accuracy of CHA2DS2VASc Score, and Development of Predictive Accuracy Model Using Machine Learning for Ischemic Stroke in Cardiac Amyloidosis
46. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases
47. Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways
48. Effects of bariatric surgery on cardiovascular‐related acute care use in patients with hypertrophic cardiomyopathy
49. In the thick of it: hereditary cardiac amyloidosis identified by 124I-AT-01 PET imaging but not cardiac MRI or SPECT 99mTc pyrophosphate scintigraphy
50. Limited English Proficiency in Older Adults Referred to the Cardiovascular Team
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.